HAEM5:Adult T-cell leukaemia/lymphoma - Revision history

Richard.Glen: Section title fix

2026-04-21T18:24:38Z

Section title fix

← Older revision		Revision as of 13:24, 21 April 2026
Line 490:		Line 490:
	\|}		\|}

	== Genetic Diagnostic Testing ~~Method~~ ==		== Genetic Diagnostic Testing Methods ==
	Initial diagnosis of ATLL should include a comprehensive physical exam with skin evaluation and CT scans of the chest, abdomen and pelvis. The laboratory evaluation should include: a complete blood count (CBC), metabolic panel (serum electrolyte levels, calcium, creatinine and blood urea nitrogen) and serum LDH levels. Testing methods including PCR, Flow Cytometry, ELISA, serology, and immunohistochemistry in addition to morphologic studies may be employed to diagnose ATLL<ref name=":4">NCCN Clinical Practice Guidelines in Oncology, T-Cell Lymphomas, Version 1.2021. Available at NCCN.org.</ref>.		Initial diagnosis of ATLL should include a comprehensive physical exam with skin evaluation and CT scans of the chest, abdomen and pelvis. The laboratory evaluation should include: a complete blood count (CBC), metabolic panel (serum electrolyte levels, calcium, creatinine and blood urea nitrogen) and serum LDH levels. Testing methods including PCR, Flow Cytometry, ELISA, serology, and immunohistochemistry in addition to morphologic studies may be employed to diagnose ATLL<ref name=":4">NCCN Clinical Practice Guidelines in Oncology, T-Cell Lymphomas, Version 1.2021. Available at NCCN.org.</ref>.

Bailey.Glen at 20:42, 20 April 2026

2026-04-20T20:42:46Z

← Older revision		Revision as of 15:42, 20 April 2026
Line 455:		Line 455:
	\|Amplification		\|Amplification
	\|		\|
	\|}<center><span style="color:Maroon">'''End of V4 Section'''</span>		\|}<center><span style="color:Maroon">'''End of V4 Section'''</span> </center>

	== Epigenomic Alterations ==		== Epigenomic Alterations ==

Bailey.Glen: Undo revision 21102 by Bailey.Glen (talk)

2026-04-20T20:41:55Z

Undo revision 21102 by Bailey.Glen (talk)

← Older revision		Revision as of 15:41, 20 April 2026
Line 455:		Line 455:
	\|Amplification		\|Amplification
	\|		\|
	\|}		\|}<center><span style="color:Maroon">'''End of V4 Section'''</span>

	== Epigenomic Alterations ==		== Epigenomic Alterations ==

Bailey.Glen at 20:39, 20 April 2026

2026-04-20T20:39:45Z

← Older revision		Revision as of 15:39, 20 April 2026
Line 471:		Line 471:
	Chemokine receptors including CCR4 and CCR7 are responsible for the infiltration of neoplastic cells into other organs along with activation of PI3K/AKT signaling.		Chemokine receptors including CCR4 and CCR7 are responsible for the infiltration of neoplastic cells into other organs along with activation of PI3K/AKT signaling.

	The epigenetic mechanism is also exploited to alter gene expression and promote ATLL progression as explained above~~<center><center>~~		The epigenetic mechanism is also exploited to alter gene expression and promote ATLL progression as explained above
	~~<center><center>~~
	~~<center>~~
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
Line 504:		Line 503:

	== References ==		== References ==
	~~<center><references /><center><center><center>~~
	~~<center>~~
	~~<center><center><center>~~
	~~<center>~~
	~~<center>~~
	~~<center>~~
	~~<center>~~
	~~<center>~~
	<references />		<references />

Bailey.Glen at 20:37, 20 April 2026

2026-04-20T20:37:46Z

← Older revision		Revision as of 15:37, 20 April 2026
Line 455:		Line 455:
	\|Amplification		\|Amplification
	\|		\|
	\|}~~<center><span style="color:Maroon">'''End of V4 Section'''</span>~~		\|}

	== Epigenomic Alterations ==		== Epigenomic Alterations ==

Sumire.Kitahara at 04:29, 7 January 2026

2026-01-07T04:29:21Z

← Older revision		Revision as of 23:29, 6 January 2026
Line 513:		Line 513:
	<center>		<center>
	<references />		<references />

	~~<br />~~

	==Notes==		==Notes==
	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.		<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership\|''<u>Associate Editor</u>'']] or other CCGA representative. When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author.

	Prior Author(s):		Prior Author(s):

			Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG



	<nowiki>*</nowiki>''Citation of this Page'': “Adult T-cell leukaemia/lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Adult_T-cell_leukaemia/lymphoma</nowiki>.		<nowiki>*</nowiki>''Citation of this Page'': “Adult T-cell leukaemia/lymphoma”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Adult_T-cell_leukaemia/lymphoma</nowiki>.
	[[Category:HAEM5]]		[[Category:HAEM5]]
	[[Category:DISEASE]]		[[Category:DISEASE]]
	[[Category:Diseases A]]		[[Category:Diseases A]]

Sumire.Kitahara: /* WHO Classification of Disease */

2026-01-07T04:23:43Z

WHO Classification of Disease

← Older revision		Revision as of 23:23, 6 January 2026
Line 42:		Line 42:

	{\| class="wikitable"		{\| class="wikitable"
	\|+
	\|Acceptable		\|Acceptable
	\|Adult T-cell leukaemia/lymphoma, HTLV-1 associated		\|Adult T-cell leukaemia/lymphoma, HTLV-1 associated
Line 457:		Line 456:
	\|		\|
	\|}<center><span style="color:Maroon">'''End of V4 Section'''</span>		\|}<center><span style="color:Maroon">'''End of V4 Section'''</span>
	~~----~~
	~~==Epigenomic Alterations==~~
	~~<center><center>~~
	Epigenetic alterations also result in dysregulated TCR/NF-κB signaling in ATLL. DNA hypermethylation of CpG islands is detected in 1/3<sup>rd</sup> of all ATLL patients. As a result, genes involved in Cys2-His2 (C2H2) zinc finger genes and those encoding MHC class I molecules are silenced<ref name=":1" />.

	ATLL patients have high expression of polycomb repressive complex (PRC) 2 components like EZH2, its homolog EZH1 and H3K27 methylase causing accumulation of trimethylation of H3K27 and altering the expression of over half of the genes. The severity of the disease is linked to continued down regulation of genes<ref>{{Cite journal\|last=Fujikawa\|first=Dai\|last2=Nakagawa\|first2=Shota\|last3=Hori\|first3=Makoto\|last4=Kurokawa\|first4=Naoya\|last5=Soejima\|first5=Ai\|last6=Nakano\|first6=Kazumi\|last7=Yamochi\|first7=Tadanori\|last8=Nakashima\|first8=Makoto\|last9=Kobayashi\|first9=Seiichiro\|date=2016-04-07\|title=Polycomb-dependent epigenetic landscape in adult T-cell leukemia\|url=https://pubmed.ncbi.nlm.nih.gov/26773042\|journal=Blood\|volume=127\|issue=14\|pages=1790–1802\|doi=10.1182/blood-2015-08-662593\|issn=1528-0020\|pmid=26773042}}</ref>.		== Epigenomic Alterations ==
			Epigenetic alterations also result in dysregulated TCR/NF-κB signaling in ATLL. DNA hypermethylation of CpG islands is detected in 1/3<sup>rd</sup> of all ATLL patients. As a result, genes involved in Cys2-His2 (C2H2) zinc finger genes and those encoding MHC class I molecules are silenced<ref name=":1" />.

			ATLL patients have high expression of polycomb repressive complex (PRC) 2 components like EZH2, its homolog EZH1 and H3K27 methylase causing accumulation of trimethylation of H3K27 and altering the expression of over half of the genes. The severity of the disease is linked to continued down regulation of genes<ref>{{Cite journal\|last=Fujikawa\|first=Dai\|last2=Nakagawa\|first2=Shota\|last3=Hori\|first3=Makoto\|last4=Kurokawa\|first4=Naoya\|last5=Soejima\|first5=Ai\|last6=Nakano\|first6=Kazumi\|last7=Yamochi\|first7=Tadanori\|last8=Nakashima\|first8=Makoto\|last9=Kobayashi\|first9=Seiichiro\|date=2016-04-07\|title=Polycomb-dependent epigenetic landscape in adult T-cell leukemia\|url=https://pubmed.ncbi.nlm.nih.gov/26773042\|journal=Blood\|volume=127\|issue=14\|pages=1790–1802\|doi=10.1182/blood-2015-08-662593\|issn=1528-0020\|pmid=26773042}}</ref>.

	==Genes and Main Pathways Involved==		== Genes and Main Pathways Involved ==
	~~<center>~~
	The most important genes involved in the development and progress of ATLL are the Tax and HBZ contributed by the HTLV-1 virus and genes listed in gene mutations table (above) from the host. The main pathways involved are TCR-NF-κB signaling by gain of function and amplifications in PLCG1, VAV1 and FYN, CD28, PRKCB, CARD11, IRF4 and RHOA; and loss of function mutations or deletions in CBLB, TRAF, TNFAIP3 and CSNK1A1<ref name=":1" />.		The most important genes involved in the development and progress of ATLL are the Tax and HBZ contributed by the HTLV-1 virus and genes listed in gene mutations table (above) from the host. The main pathways involved are TCR-NF-κB signaling by gain of function and amplifications in PLCG1, VAV1 and FYN, CD28, PRKCB, CARD11, IRF4 and RHOA; and loss of function mutations or deletions in CBLB, TRAF, TNFAIP3 and CSNK1A1<ref name=":1" />.

Line 474:		Line 471:
	Chemokine receptors including CCR4 and CCR7 are responsible for the infiltration of neoplastic cells into other organs along with activation of PI3K/AKT signaling.		Chemokine receptors including CCR4 and CCR7 are responsible for the infiltration of neoplastic cells into other organs along with activation of PI3K/AKT signaling.

	The epigenetic mechanism is also exploited to alter gene expression and promote ATLL progression as explained above.		The epigenetic mechanism is also exploited to alter gene expression and promote ATLL progression as explained above<center><center>
			<center><center>
			<center>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
Line 490:		Line 489:
	\|<span class="blue-text">EXAMPLE:</span> Histone modification, chromatin remodeling		\|<span class="blue-text">EXAMPLE:</span> Histone modification, chromatin remodeling
	\|<span class="blue-text">EXAMPLE:</span> Abnormal gene expression program		\|<span class="blue-text">EXAMPLE:</span> Abnormal gene expression program
	\|-
	\|
	\|
	\|
	\|}		\|}
	==Genetic Diagnostic Testing ~~Methods~~==
	~~<center>~~		== Genetic Diagnostic Testing Method ==
	Initial diagnosis of ATLL should include a comprehensive physical exam with skin evaluation and CT scans of the chest, abdomen and pelvis. The laboratory evaluation should include: a complete blood count (CBC), metabolic panel (serum electrolyte levels, calcium, creatinine and blood urea nitrogen) and serum LDH levels. Testing methods including PCR, Flow Cytometry, ELISA, serology, and immunohistochemistry in addition to morphologic studies may be employed to diagnose ATLL<ref name=":4">NCCN Clinical Practice Guidelines in Oncology, T-Cell Lymphomas, Version 1.2021. Available at NCCN.org.</ref>.		Initial diagnosis of ATLL should include a comprehensive physical exam with skin evaluation and CT scans of the chest, abdomen and pelvis. The laboratory evaluation should include: a complete blood count (CBC), metabolic panel (serum electrolyte levels, calcium, creatinine and blood urea nitrogen) and serum LDH levels. Testing methods including PCR, Flow Cytometry, ELISA, serology, and immunohistochemistry in addition to morphologic studies may be employed to diagnose ATLL<ref name=":4">NCCN Clinical Practice Guidelines in Oncology, T-Cell Lymphomas, Version 1.2021. Available at NCCN.org.</ref>.

	==Familial Forms==		== Familial Forms ==
	<~~center~~>		Put your text here <span style="color:#0070C0">(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'') </span>

			== Additional Information ==
			Put your text here

	Put ~~your text~~ here <span style="color:#0070C0">(''Instructions: ~~Include associated hereditary conditions/syndromes that cause~~ this ~~entity~~ or ~~are caused~~ by ~~this entity~~.'') </span>		== Links ==
			Put a link here or anywhere appropriate in this page <span style="color:#0070C0">(''Instructions: Highlight the text to which you want to add a link in this section or elsewhere, select the "Link" icon at the top of the wiki page, and search the name of the internal page to which you want to link this text, or enter an external internet address by including the "<nowiki>http://www</nowiki>." portion.'')</span>

	==~~Additional Information~~==		== References ==
			<center><references /><center><center><center>
			<center>
			<center><center><center>
			<center>
			<center>
			<center>
	<center>		<center>
	~~Put your text here~~

	~~==Links==~~
	<center>		<center>


	Put a link here or anywhere appropriate in this page <span style="color:#0070C0">(''Instructions: Highlight the text to which you want to add a link in this section or elsewhere, select the "Link" icon at the top of the wiki page, and search the name of the internal page to which you want to link this text, or enter an external internet address by including the "<nowiki>http://www</nowiki>." portion.'')</span>
	~~==References==~~
	<references />		<references />

Sumire.Kitahara at 03:38, 24 September 2025

2025-09-24T03:38:27Z

← Older revision		Revision as of 22:38, 23 September 2025
Line 459:		Line 459:
	----		----
	==Epigenomic Alterations==		==Epigenomic Alterations==
	<center>		<center><center>
	Epigenetic alterations also result in dysregulated TCR/NF-κB signaling in ATLL. DNA hypermethylation of CpG islands is detected in 1/3<sup>rd</sup> of all ATLL patients. As a result, genes involved in Cys2-His2 (C2H2) zinc finger genes and those encoding MHC class I molecules are silenced<ref name=":1" />.		Epigenetic alterations also result in dysregulated TCR/NF-κB signaling in ATLL. DNA hypermethylation of CpG islands is detected in 1/3<sup>rd</sup> of all ATLL patients. As a result, genes involved in Cys2-His2 (C2H2) zinc finger genes and those encoding MHC class I molecules are silenced<ref name=":1" />.

Sumire.Kitahara: /* Epigenomic Alterations */

2025-09-24T03:37:54Z

Epigenomic Alterations

← Older revision		Revision as of 22:37, 23 September 2025
Line 459:		Line 459:
	----		----
	==Epigenomic Alterations==		==Epigenomic Alterations==
			<center>
	Epigenetic alterations also result in dysregulated TCR/NF-κB signaling in ATLL. DNA hypermethylation of CpG islands is detected in 1/3<sup>rd</sup> of all ATLL patients. As a result, genes involved in Cys2-His2 (C2H2) zinc finger genes and those encoding MHC class I molecules are silenced<ref name=":1" />.		Epigenetic alterations also result in dysregulated TCR/NF-κB signaling in ATLL. DNA hypermethylation of CpG islands is detected in 1/3<sup>rd</sup> of all ATLL patients. As a result, genes involved in Cys2-His2 (C2H2) zinc finger genes and those encoding MHC class I molecules are silenced<ref name=":1" />.

Line 465:		Line 465:

	==Genes and Main Pathways Involved==		==Genes and Main Pathways Involved==
			<center>
	The most important genes involved in the development and progress of ATLL are the Tax and HBZ contributed by the HTLV-1 virus and genes listed in gene mutations table (above) from the host. The main pathways involved are TCR-NF-κB signaling by gain of function and amplifications in PLCG1, VAV1 and FYN, CD28, PRKCB, CARD11, IRF4 and RHOA; and loss of function mutations or deletions in CBLB, TRAF, TNFAIP3 and CSNK1A1<ref name=":1" />.		The most important genes involved in the development and progress of ATLL are the Tax and HBZ contributed by the HTLV-1 virus and genes listed in gene mutations table (above) from the host. The main pathways involved are TCR-NF-κB signaling by gain of function and amplifications in PLCG1, VAV1 and FYN, CD28, PRKCB, CARD11, IRF4 and RHOA; and loss of function mutations or deletions in CBLB, TRAF, TNFAIP3 and CSNK1A1<ref name=":1" />.

Line 496:		Line 496:
	\|}		\|}
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==
			<center>
	Initial diagnosis of ATLL should include a comprehensive physical exam with skin evaluation and CT scans of the chest, abdomen and pelvis. The laboratory evaluation should include: a complete blood count (CBC), metabolic panel (serum electrolyte levels, calcium, creatinine and blood urea nitrogen) and serum LDH levels. Testing methods including PCR, Flow Cytometry, ELISA, serology, and immunohistochemistry in addition to morphologic studies may be employed to diagnose ATLL<ref name=":4">NCCN Clinical Practice Guidelines in Oncology, T-Cell Lymphomas, Version 1.2021. Available at NCCN.org.</ref>.		Initial diagnosis of ATLL should include a comprehensive physical exam with skin evaluation and CT scans of the chest, abdomen and pelvis. The laboratory evaluation should include: a complete blood count (CBC), metabolic panel (serum electrolyte levels, calcium, creatinine and blood urea nitrogen) and serum LDH levels. Testing methods including PCR, Flow Cytometry, ELISA, serology, and immunohistochemistry in addition to morphologic studies may be employed to diagnose ATLL<ref name=":4">NCCN Clinical Practice Guidelines in Oncology, T-Cell Lymphomas, Version 1.2021. Available at NCCN.org.</ref>.

	==Familial Forms==		==Familial Forms==
			<center>


	Put your text here <span style="color:#0070C0">(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'') </span>		Put your text here <span style="color:#0070C0">(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'') </span>

	==Additional Information==		==Additional Information==
			<center>
	Put your text here		Put your text here

	==Links==		==Links==
			<center>

Sumire.Kitahara: /* Individual Region Genomic Gain/Loss/LOH */

2025-09-24T03:36:15Z

Individual Region Genomic Gain/Loss/LOH

← Older revision		Revision as of 22:36, 23 September 2025
Line 98:		Line 98:
	==Individual Region Genomic Gain/Loss/LOH==		==Individual Region Genomic Gain/Loss/LOH==

	ATLL with high number of chromosomal imbalances is associated with poor survival<ref>{{Cite journal\|last=Itoyama\|first=T.\|last2=Chaganti\|first2=R. S.\|last3=Yamada\|first3=Y.\|last4=Tsukasaki\|first4=K.\|last5=Atogami\|first5=S.\|last6=Nakamura\|first6=H.\|last7=Tomonaga\|first7=M.\|last8=Ohshima\|first8=K.\|last9=Kikuchi\|first9=M.\|date=2001-06-01\|title=Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki\|url=https://pubmed.ncbi.nlm.nih.gov/11369658\|journal=Blood\|volume=97\|issue=11\|pages=3612–3620\|doi=10.1182/blood.v97.11.3612\|issn=0006-4971\|pmid=11369658}}</ref><ref>{{Cite journal\|last=Tsukasaki\|first=K.\|last2=Krebs\|first2=J.\|last3=Nagai\|first3=K.\|last4=Tomonaga\|first4=M.\|last5=Koeffler\|first5=H. P.\|last6=Bartram\|first6=C. R.\|last7=Jauch\|first7=A.\|date=2001-06-15\|title=Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: correlation with clinical course\|url=https://pubmed.ncbi.nlm.nih.gov/11389029\|journal=Blood\|volume=97\|issue=12\|pages=3875–3881\|doi=10.1182/blood.v97.12.3875\|issn=0006-4971\|pmid=11389029}}</ref><ref name=":0">{{Cite journal\|last=Oshiro\|first=Aya\|last2=Tagawa\|first2=Hiroyuki\|last3=Ohshima\|first3=Koichi\|last4=Karube\|first4=Kennosuke\|last5=Uike\|first5=Naokuni\|last6=Tashiro\|first6=Yukie\|last7=Utsunomiya\|first7=Atae\|last8=Masuda\|first8=Masato\|last9=Takasu\|first9=Nobuyuki\|date=2006-06-01\|title=Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/16484591\|journal=Blood\|volume=107\|issue=11\|pages=4500–4507\|doi=10.1182/blood-2005-09-3801\|issn=0006-4971\|pmid=16484591}}</ref><ref name=":2">{{Cite journal\|last=Kataoka\|first=Keisuke\|last2=Iwanaga\|first2=Masako\|last3=Yasunaga\|first3=Jun-Ichirou\|last4=Nagata\|first4=Yasunobu\|last5=Kitanaka\|first5=Akira\|last6=Kameda\|first6=Takuro\|last7=Yoshimitsu\|first7=Makoto\|last8=Shiraishi\|first8=Yuichi\|last9=Sato-Otsubo\|first9=Aiko\|date=01 11, 2018\|title=Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/29084771\|journal=Blood\|volume=131\|issue=2\|pages=215–225\|doi=10.1182/blood-2017-01-761874\|issn=1528-0020\|pmc=5757690\|pmid=29084771}}</ref>.		ATLL with high number of chromosomal imbalances is associated with poor survival<ref>{{Cite journal\|last=Itoyama\|first=T.\|last2=Chaganti\|first2=R. S.\|last3=Yamada\|first3=Y.\|last4=Tsukasaki\|first4=K.\|last5=Atogami\|first5=S.\|last6=Nakamura\|first6=H.\|last7=Tomonaga\|first7=M.\|last8=Ohshima\|first8=K.\|last9=Kikuchi\|first9=M.\|date=2001-06-01\|title=Cytogenetic analysis and clinical significance in adult T-cell leukemia/lymphoma: a study of 50 cases from the human T-cell leukemia virus type-1 endemic area, Nagasaki\|url=https://pubmed.ncbi.nlm.nih.gov/11369658\|journal=Blood\|volume=97\|issue=11\|pages=3612–3620\|doi=10.1182/blood.v97.11.3612\|issn=0006-4971\|pmid=11369658}}</ref><ref name=":3">{{Cite journal\|last=Tsukasaki\|first=K.\|last2=Krebs\|first2=J.\|last3=Nagai\|first3=K.\|last4=Tomonaga\|first4=M.\|last5=Koeffler\|first5=H. P.\|last6=Bartram\|first6=C. R.\|last7=Jauch\|first7=A.\|date=2001-06-15\|title=Comparative genomic hybridization analysis in adult T-cell leukemia/lymphoma: correlation with clinical course\|url=https://pubmed.ncbi.nlm.nih.gov/11389029\|journal=Blood\|volume=97\|issue=12\|pages=3875–3881\|doi=10.1182/blood.v97.12.3875\|issn=0006-4971\|pmid=11389029}}</ref><ref name=":0">{{Cite journal\|last=Oshiro\|first=Aya\|last2=Tagawa\|first2=Hiroyuki\|last3=Ohshima\|first3=Koichi\|last4=Karube\|first4=Kennosuke\|last5=Uike\|first5=Naokuni\|last6=Tashiro\|first6=Yukie\|last7=Utsunomiya\|first7=Atae\|last8=Masuda\|first8=Masato\|last9=Takasu\|first9=Nobuyuki\|date=2006-06-01\|title=Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/16484591\|journal=Blood\|volume=107\|issue=11\|pages=4500–4507\|doi=10.1182/blood-2005-09-3801\|issn=0006-4971\|pmid=16484591}}</ref><ref name=":2">{{Cite journal\|last=Kataoka\|first=Keisuke\|last2=Iwanaga\|first2=Masako\|last3=Yasunaga\|first3=Jun-Ichirou\|last4=Nagata\|first4=Yasunobu\|last5=Kitanaka\|first5=Akira\|last6=Kameda\|first6=Takuro\|last7=Yoshimitsu\|first7=Makoto\|last8=Shiraishi\|first8=Yuichi\|last9=Sato-Otsubo\|first9=Aiko\|date=01 11, 2018\|title=Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/29084771\|journal=Blood\|volume=131\|issue=2\|pages=215–225\|doi=10.1182/blood-2017-01-761874\|issn=1528-0020\|pmc=5757690\|pmid=29084771}}</ref>.
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
Line 196:		Line 196:
	\|14		\|14
	\|Gain		\|Gain
	\|14q32<ref name=":0" />		\|14q32<ref name=":0" /><ref name=":3" />
	\|		\|
	\|		\|